Houston, Texas – Researchers at The University of Texas MD Anderson Cancer Center recently discovered a new blood-based biomarker. This breakthrough could help identify cancer risk in people with Lynch Syndrome. The study, published in Nature Communications on April 3, 2026, offers a less invasive way to assess who might develop cancer.
Understanding Lynch Syndrome
Lynch Syndrome is a common inherited condition. It involves mutations in DNA mismatch repair genes. These mutations significantly increase a person's risk of developing certain cancers, often at a younger age. About 1 in 279 to 1 in 440 people in the general population have Lynch Syndrome.
People with Lynch Syndrome face a higher risk for colorectal and endometrial cancers. They also have increased risks for ovarian, stomach, small intestine, urinary tract, brain, skin, and pancreatic cancers. Current methods to monitor these patients often involve frequent and invasive procedures. These include regular colonoscopies.[clpmag+7]
Challenges in Current Cancer Detection
Current surveillance for Lynch Syndrome patients relies heavily on invasive tests. Colonoscopies are crucial for detecting colorectal cancer. However, patients may find these procedures burdensome. This can lead to lower compliance over time. There is a clear need for simpler, more accessible screening options. New genetic markers are also being explored in stool samples.[pubmed+1]
A New Blood-Based Biomarker
The MD Anderson research team identified a blood-based biomarker. This biomarker uses T cell receptor (TCR) sequencing to find unique immune signatures. These signatures can help clinicians gauge an individual's cancer risk. This allows for personalized prevention strategies.
Eduardo Vilar-Sanchez, M.D., Ph.D., led the study. He is the chair ad interim of Clinical Cancer Prevention at MD Anderson. Dr. Vilar-Sanchez highlighted the importance of this discovery. "Providing a potential non-invasive blood test to track cancer risk and immune activity in patients with Lynch Syndrome is a tremendous step forward for this patient population," he said. He added that these insights into immune responses can help personalize monitoring and prevention.[clpmag+12]
How the New Test Works
The researchers analyzed T cell receptors. These receptors help the immune system find and attack tumor-specific neoantigens. Neoantigens are protein fragments on cancer cells. They are created by DNA mutations common in Lynch Syndrome-related cancers.
The study looked at peripheral blood mononuclear cell samples from 277 participants. This group included 102 Lynch Syndrome cancer survivors. It also included 130 Lynch Syndrome carriers who had no history of cancer. A control group of 45 individuals without Lynch Syndrome was also part of the study. The team also sequenced TCRs in colorectal tissues from three cancers and 11 pre-cancers.[clpmag+4]
The study found specific T cells expanded in colon tumors and pre-cancer tissues. These cells responded to tumor-specific neoantigens. Up to 41% of these expanded TCRs were also found in the blood of Lynch Syndrome carriers. They were not found in people without Lynch Syndrome. This suggests the immune system is actively watching for early signs of cancer.[clpmag+1]
The researchers used this data to create a classification model. This model could tell Lynch Syndrome carriers apart from control samples. It did this by simply looking at TCR patterns in their blood. The model could identify carriers even if they had no cancer history.[clpmag+2]
Impact and Future Directions
This new blood test could become a non-invasive tool. It may help with early cancer detection and risk assessment. It could also lead to more personalized surveillance for Lynch Syndrome patients. The findings improve our understanding of T cell responses in these individuals. This could provide tailored insights for monitoring and treatments.
While the findings are promising, further validation is necessary. This new biomarker has the potential to transform how doctors monitor patients with Lynch Syndrome. It could offer a much-needed alternative to invasive procedures. This would improve the lives of many at-risk individuals.[clpmag+3]
